Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children

International Journal of Clinical Pharmacology and Therapeutics

Volumn 40, Issue 11, 2002, Pages 485-492

  Kanamori, M ^a   Takahashi, H ^a   Echizen, H ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Body surface area; Children; Liver weight; Pediatric dosages

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; PHENYTOIN; SANDIMMUM; THEOPHYLLINE; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ADOLESCENT; ADULT; AGE; ARTICLE; AUTOPSY; BODY SURFACE; BODY WEIGHT; CALCULATION; CHILD DEVELOPMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DRUG CLEARANCE; DRUG FORMULATION; DRUG METABOLISM; HUMAN; LIVER METABOLISM; LIVER WEIGHT; MEDICAL LITERATURE; MEDLINE; PRESCHOOL CHILD; BIOLOGICAL MODEL; CHILD; GROWTH, DEVELOPMENT AND AGING; INFANT; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; NEWBORN; ORAL DRUG ADMINISTRATION; ORGAN SIZE; PHYSIOLOGY;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; ARYL HYDROCARBON HYDROXYLASES; BODY SURFACE AREA; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INFANT; INFANT, NEWBORN; LIVER; METABOLIC CLEARANCE RATE; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; ORGAN SIZE; PHENYTOIN; THEOPHYLLINE;

EID: 0036847559     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP40485     Document Type: Article

References (46)

1. Arnold JD, Hill GN, Sansom LN 1981 A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission. Eur J Clin Pharmacol 20: 443-447
2. Baker JR Jr, Moessner H, Gonzalez U, Grabenstein J, Renard R, DeNapoli T, Summers R, Schuster B 1988 Clinical relevance of the substitution of different brands of sustained-release theophylline. J Allergy Clin Immunol 81: 664-673
3. Bauer LA, Blouin R 1983 Phenytoin: Michaelis-Menten pharmacokinetics in Caucasian pediatric patients. Clin Pharmacokinet 8: 545-549
4. Benet LZ, Oie S, Schwartz JB 1996 Design and optimization of dosage regimens; pharmacokinetic data. In: Hardman JG, Limbird LE (eds) Goodman and Gilman's: The Pharmacological Basis of Therapeutics (9th ed). McGraw-Hill, New York, pp 1707-1792
5. Blain PG, Mucklow JC, Bacon CJ, Rawlins MD 1981 Pharmacokinetics of phenytoin in children. Br J Clin Pharmacol 12: 659-661
6. Blanco JG, Harrison PL, Evans WE, Relling MV 2000 Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos 28: 379-382
7. Chiba K, Ishizaki T, Miura H, Minagawa K 1980 Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. J Pediatr 90: 479-484
8. Coppoletta JM, Wolbach SB 1933 Body length and organ weights of infants and children: a study of the body length and normal weights of the more important vital organs of the body between birth and twelve years of age. Am J Pathol 9: 55-70
9. Crom WR, Relling MV, Christensen ML, Rivera GK, Evans WE 1991 Age-related differences in hepatid drug clearance in children: studies with lorazepam and antipyrine. Clin Pharmacol Ther 50: 132-140
10. Crowley JJ, Koup JR, Cusack BJ, Ludden TM, Vestal RE 1987 Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. Eur J Clin Pharmacol 32: 141-148
11. Curless RG, Walson PD, Carter DE 1976 Phenytoin kinetics in children. Neurology 26: 715-720
12. Dodson WE 1982 Nonlinear kinetics of phenytoin in children. Neurology 32: 42-48
13. Ellis EF, Koysooko R, Levy G 1976 Pharmacokinetics of theophylline in children with asthma. Pediatrics 58: 542-547
14. Engel G, Hofmann U, Heidelmann H, Cosme J, Eichelbaum M 1996 Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxyantipyrine, and norantipyrine formation. Clin Pharmacol Ther 59: 613-623
15. Goldstein JA, de Morais SM 1994 Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299
16. Grygiel JJ, Ward H, Ogborne M, Goldin A, Birkett DJ 1983 Relationship between plasma theophylline clearance, liver volume and BW in children and adults. Eur J Clin Pharmacol 24: 529-532
17. Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL 1991 Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol 5: 1-4
18. International Commission of Radiological Protection (ICRP) Publication 23 1975 Reference Man: Anatomical, Physiological and Metabolic Characteristics. ICRP, Elsevier Science, Amsterdam
19. Jacqz-Aigrain E, Montes C, Brun P, Loirat C 1994 Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. Br J Clin Pharmacol 47: 61-65
20. Kelly HW, Murphy S 1979 Serum theophylline levels in asthmatic children receiving sustained-release theophylline tablets. Am J Hosp Pharm 36: 1698-1701
21. Kraus DM, Fischer JH, Reitz SJ, Kecskes SA, Yeh TF, McCulloch KM, Tung EC, Cwik MJ 1993 Alterations in theophylline metabolism during the first year of life. Clin Pharmacol Ther 54: 351-359
22. Kronbach T, Fischer V, Meyer UA 1988 Cyclosporine metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630-635
23. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T 1997 Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247: 625-634
24. Lerman J, Strong HA, LeDez KM, Swartz J, Rider MJ, Burrows FA 1989 Effects of age on the serum concentration of alpha 1-acid glycoprotein and the binding of lidocaine in pediatric patients. Clin Pharmacol Ther 46: 219-225
25. Leung P, Kalisker A, Bell TD 1977 Variation in theophylline clearance rate within chronic childhood asthma. J Allergy Clin Immunol 59: 440-444
26. Loughnan PM, Sitar DS, Ogilvie RI, Eisen A, Fox Z, Neims AH 1976 Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. J Pediatr 88: 874-879
27. Maxwell GM 1989 Pediatric drug dosing: body weight versus surface area. Drugs 37: 113-115
28. Metcoff J, Stare F 1947 The physiologic and clinical significance of plasma proteins and protein metabolites. N Engl J Med 236: 26-35
29. Mochon M, Cooney G, Lum B et al 1996 Pharmacokinetics of cyclosporine after renal transplant in children. J Clin Pharmacol 36: 580-586
30. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE 1995 Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 23: 1110-1116
31. Odani A, Hashimoto Y, Takayanagi K et al 1996 Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull 19: 444-448
32. Reynaud-Gaubert M, Viard L, Girault D, Bertault-Perez P, Guignard M, Metras D, Fuentes P 1997 Improved absorption and bioavailability of cyclosporin A: from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis. Transplant Proc 29: 2450-2453
33. Richens A, Dunlop A 1975 Serum-phenytoin levels in management of epilepsy. Lancet 2: 247-248
34. Roberts CJ, Jackson L, Halliwell M, Branch RA 1976 The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. Br J Clin Pharmacol 3: 907-913
35. Rosen JP, Danish M, Ragni MC, Saccar CL, Yaffe SJ, Lecks HI 1979 Theophylline pharmacokinetics in the young infant. Pediatrics 64: 248-251
36. Rylance GW, Moreland TA, Cowan MD, Clark DC 1982 Liver volume estimation using ultrasound scanning. Arch Dis Child 57: 283-285
37. Sinha R, Fisch G, Teague B et al 2002 Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346: 802-810
38. Simons R, Simons KJ 1978 Pharmacokinetics of theophylline in infancy. J Clin Pharmacol 18: 472-476
39. Slotfeldt ML, Johnson CE, Grambau G, Weg JG 1979 Reliability of theophylline clearance in determining chronic dosage regimens. Am J Hosp Pharm 36: 66-68
40. Takada K, Yoshikawa H, Muranishi S, Nagano S, Fukunishi T 1987 A preliminary pharmacokinetic study of cyclosporin A in 10 Japanese renal transplant patients. Int J Clin Pharmacol Ther Toxicol 25: 438-442
41. Tikahashi H, Ishikawa S, Nomoto S et al 2000 Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 68: 541-555
42. Tallman MS, Nemunaitis JJ, McGuire TR et al 1988 Comparison of two intravenous cyclosporine infusion schedules in marrow transplant recipients. Transplantation 45: 810-813
43. Tjia JF, Colbert J, Back DJ 1996 Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 276: 912-917
44. Urata K, Kawasaki S, Matsunami H et al 1995 Calculation of child and adult standard liver volume for liver transplantation. Hepatology 21: 1317-1321
45. Walson PD, Strunk RC, Taussig LM 1977 Intrapatient variability in theophylline kinetics. J Pediatr 91: 321-324
46. Weinberger MW, Matthay RA, Ginchansky EJ, Chidsey CA, Petty TL 1976 Intravenous aminophylline dosage. JAMA 235: 2110-2113